News & Events
Published On: 10/11/2021
Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
Target RWE participated in the virtual United European Gastroenterology (UEG) Week in October 2021 to share new real-world data findings from a recent TARGET-IBD poster- Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis.
The TARGET-IBD analysis focused on assessing the associations between clinical characteristics and loss of remission (LOR) in a real-world US-based cohort of Crohn’s disease (CD) patients in endoscopic remission. The analysis found that 53.8% of patients experienced LOR during follow-up to second colonoscopy. In addition, ileal disease at index was significantly associated with future LOR compared to isolated colonic disease. Furthermore, evidence of histologic inflammation was associated with twice the odds of LOR and was a predictor of subsequent LOR.
“The findings presented at UEG Week highlight the need for future research to be more focused on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors,” said Julie M. Crawford, MD, Senior Director of Scientific and Medical Affairs.
TARGET-IBD is an active 5-year longitudinal, observational study of more than 4,600 adult and pediatric patients with IBD receiving usual care from 36 academic and community centers throughout the U.S. Real-world data is collected retrospectively for three years from the time of the patient's date of consent and patients are also followed prospectively for a minimum of five years. The robust TARGET-IBD cohort allows for the collection of effectiveness and safety data upon new drug approvals.
Learn more about Target RWE’s publications here.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
11/04/2022New TARGET-NASH Real World Data Show Non-Alcoholic Fatty Liver Disease Severity and Gender Linked to Disparities in Polypharmacy
10/18/2022Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative
08/25/2022New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
08/24/2022Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition
08/23/2022Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022